Maravai LifeSciences Holdings Inc. Class A Common Stock vs NextEra Energy, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while NextEra Energy, Inc. trades at $78.7 (market cap $163.17B). The key difference: NextEra Energy, Inc. is far larger — about 167.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and NextEra Energy, Inc. pays a 3.19% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and NextEra Energy, Inc. for 83 Days on average.
| MRVI | NEE | |
|---|---|---|
Market Cap | $972.90M | $163.17B |
Volume | 4,325,710 | 9,492,162 |
Sector | Health | Utilities |
52-Week High | $9.00 | $97.88 |
52-Week Low | $2.83 | $75.49 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $1.08B | $270.50B |
Dividend Yield | — | 3.19% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
NextEra Energy (NEE) trades at $78.37, down 0.18% today, with a bullish technical signal but mixed indicators. The company reported strong earnings beats in Q1 and Q2 2026, with revenue growth and a net income margin of 32.4%. Recent news highlights expansion in gas generation and a major infrastructure partnership. Analyst consensus is strongly bullish with a $96 price target, though the stock is near a 52-week low of $74.78, indicating potential value.
Outlook is positive due to robust fundamentals and growth initiatives, but risks include rising debt levels and interest rate sensitivity. The stock offers a dividend yield with upcoming payment, supporting income investors. Upside potential exists if earnings momentum continues, but macroeconomic headwinds and competitive pressures warrant caution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →